SallyAraiMD

Hematology • Stanford, CA

Hematologic Oncology

Assistant Professor, Medicine - Blood & Marrow Transplantation, Stanford University Medical Center

Join to view full profile

Dr. Arai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arai's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-0822

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1995 - 1998
University of Rochester Medical CenterResidency, Internal Medicine, 1992 - 1995
George Washington UniversityResidency, Surgery, 1991 - 1992
Geisel School of Medicine at DartmouthClass of 1991

Certifications & Licensure

CA State Medical License 2004 - 2025
IL State Medical License 2001 - 2005
MD State Medical License 1999 - 2004
NY State Medical License 1994 - 2004
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma Start of enrollment: 1994 Sep 01
Completed
Phase 2
High Dose Chemotherapy Followed By PBSC Rescue for HD Start of enrollment: 1998 Mar 01
Completed
Not Applicable
Autologous Stem Cell Rescue for Primary Amyloidosis Start of enrollment: 1998 Apr 01
Completed
Phase 2
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma Start of enrollment: 2006 Aug 01
Completed
Phase 2
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease Start of enrollment: 2006 Aug 01
Completed
Not Applicable
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Start of enrollment: 2001 Sep 01
Completed
Phase 2
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies Start of enrollment: 2006 May 01
Completed
Phase 1
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL Start of enrollment: 2009 Aug 01
Completed
Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2011 Mar 01
Completed
Phase 2
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Completed
Phase 2
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
COMPLETED
PHASE1, PHASE2
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD Start of enrollment: 2013 Jul 01
Completed
Phase 1
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies Start of enrollment: 2021 Jun 16
TERMINATED
PHASE2
Join now to see all

Publications & Presentations

PubMed

Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.
Michelle M Chin, John S Tamaresis, Laura J Johnston, Robert Lowsky, Everett Meyer
Bone Marrow Transplantation. 2025-03-01
A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis.
Eli Muchtar, Angela Dispenzieri, Vaishali Sanchorawala, Hamza Hassan, Raphael Mwangi
Bone Marrow Transplantation. 2025-02-24
Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.
Hitomi Hosoya, Mia Carleton, Kailee Tanaka, Brian Sworder, Shriya Syal
Nature Communications. 2025-02-20

Abstracts/Posters

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Sally Arai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Sally Arai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses
Sally Arai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis
Sally Arai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Immune Reconstitution and Long-Term Outcomes Following Allo-HCT with TLI-ATG and Post-Transplant Rituximab
Sally Arai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Roberto Alejandro Sica, MD, a Hematologist-Oncologist with Montefiore Medical CenterJanuary 5th, 2022
Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021
Meet Your Match: A Bone Marrow Transplantation Leads to an International FriendshipMay 10th, 2018